Yet, it should be noted that recent work of the Letai group has questioned BDA-366 as an on-target inhibitor of Bcl-2 proteins [34], indicating that BDA-366 can kill cancer cells independently of Bcl-2. This evidence concerns the gene BCL2 and cancer.